The Danish insulin maker plans to file for regulatory approval for the company’s new anti-obesity drug in Mexico, reports the Wall Street Journal.

Novo Nordisk has reportedly targeted Mexico for an early launch of the treatment due to Mexico’s high percentage of overweight people, according to a statement from Mike Doustdar, senior vice president for international operations at Novo Nordisk. The drug is based on liraglutide, the active component in Novo Nordisk’s diabetes drug Victoza.

Wall Street Journal reports further that Novo Nordisk is hoping that the drug will be approved within a year and Mike Doustar is, as quoted in the magazine, “very encouraged that this drug will come to many markets, including Mexico.”